# US 2010/0168229 A1 · Process for the preparation of optically active compounds using transfer hydrogenation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168229 A1
- Document ID: US20100168229A1
- Status: Published application
- Kind: A1
- Application number: 12/653,748
- Filed: 2009-12-17
- Published: 2010-07-01
- Earliest claimed: 2008-12-24
- Assignees: Novartis AG
- Inventors: Christian Mathes; Michael Foulkes; Martin Kesselgruber
- Web page: https://patentgrep.com/patent/US20100168229A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 269/04: from amines with formation of carbamate groups
- C07C 37/002: {by transformation of a functional group, e.g. oxo, carboxyl}
- C07C 213/02: by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
- C07C 213/08: by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- C07C 303/28: by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
- C07C 303/30: by reactions not involving the formation of esterified sulfo groups
- C07C 309/66: Methanesulfonates
- C07B 2200/07: Optical isomers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.

## Claims

### Claim 1

A process for the preparation of a compound according to the following general formula (I):
wherein
R1=C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C2-20 organohalide, an aryl, an amine or amide group; and
n=1 to 5;
said process comprising:
(a) performing an asymmetric catalytic reduction on a hydroxyphenone according to the following general formula (II):
wherein
R1=C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C2-20 organohalide, an aryl, an amine- or amide-containing group;
n=1 to 5; and
wherein said asymmetric catalytic reduction is performed using transfer hydrogenation, and
wherein said asymmetric catalytic reduction is performed using a chiral metal catalyst.

### Claim 2 (depends on 1)

The process of claim 1, wherein the amount of optically active compound (III) formed
is greater than the amount of optically active compound (IV)

### Claim 3 (depends on 2)

The process of claim 2, wherein the asymmetric catalytic reduction forms an enantiomeric excess of compound (III) to compound (IV) of from about 96%:4% or higher, about 98%:2% or higher, or about 99%:1% or higher.

### Claim 4 (depends on 3)

The process of claim 3, wherein after a crystallization step the enantiomeric excess of compound (III) to compound (IV) is from about 97%:3% or higher, about 98%:2% or higher, about 99%:1% or higher, or about >99.5%:about <0.5%, or about >99.7%:about <0.03.%.

### Claim 5 (depends on 1)

The process of claim 1, wherein n=1 in general formulas (I)-(IV).

### Claim 6 (depends on 1)

The process of claim 1, wherein n=1 in general formulas (I)-(IV) and a hydroxyl group occurs at position 3 on the aromatic ring.

### Claim 7 (depends on 1)

The process of claim 1 wherein R1 is a C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl or C2-10 organohalide.

### Claim 8 (depends on 1)

The process of claim 1 wherein R1 is selected from any of methyl, ethyl, propyl and butyl.

### Claim 9 (depends on 1)

The process of claim 1, wherein R1 is methyl and n=1 and the prepared compound is (R)-3-(1-Hydroxy-ethyl)-phenol of formula (VI):

### Claim 10 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral transition metal based catalyst.

### Claim 11 (depends on 1)

The process of claim 1 wherein the transfer hydrogenation is performed using a complexed transition metal based chiral catalyst containing multiple aryl, mono- bi-, or poly-dentate ligands.

### Claim 12 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a Ru, Rh or Ir based catalyst.

### Claim 13 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral (diphenylethylenediamine) based Ru catalyst.

### Claim 14 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral metal catalyst of structure (VII):
or
wherein
M=a transition metal:
L1=an aryl based group, a carbonyl, C2-20 alkenyl or C2-20 alkynyl; and
L2=a halide, an organohalide, a borohalide, a sulphonate, nitriles, carbenes, carbon monoxide, phosphines, a carbonyl, an amine- or amide-containing group.

### Claim 15 (depends on 14)

The process of claim 14, wherein the transition metal M is Ru, Rh or Ir.

### Claim 16 (depends on 14)

The process of claim 14, wherein L1 is p-cymene, benzene, cyclooctadiene, triphenylphosphine, or norbornadiene

### Claim 17 (depends on 14)

The process of claim 14, wherein L2 is chloride, bromide, iodide, tetrafluoroborate, tripentafluorophenylborane (i.e. BARF), mesylate, trifluoroacetate, triflate, methylallyl or acetylacetonato.

### Claim 18 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral metal catalyst of structure (VIII):

### Claim 19 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral metal catalyst selected from any one of or combination of the following: (1R,2R)-(−)-Chloro-N-(4-toluenesulfonyl-1,2-diphenylethylenediamine)(p-cymene)ruthenium; or (1R,2R)-(−)-N-4-toluenesulfonyl-1,2-diphenylethylenediamine in combination with ruthenium p-cymene chloride dimer.

### Claim 20 (depends on 1)

The process of claim 1, wherein the transfer hydrogenation is performed using a chiral metal catalyst and the catalyst is present in a range from about 0.005 mol % to about 5.0 mol %, about 0.01 mol % to about 1.0 mol % or from about 0.05 mol % to about 0.5 mol %.

### Claim 21 (depends on 1)

The process of claim 1 wherein the reduced hydroxyphenone forms a chiral alcohol which is converted via a series of steps to a chiral amino alcohol as follows:
(a) performing an activation step on the hydroxyl groups of the formed chiral alcohol to form activated hydroxy alcoholic groups and activated hydroxy phenolic groups on the chiral alcohol;
(b) performing a nucleophilic substitution on the activated hydroxy alcoholic groups; and
(c) cleaving the activated hydroxy phenolic groups to form the chiral amino alcohol.

### Claim 22 (depends on 21)

The process of claim 21, wherein the activation step uses sulfonylation.

### Claim 23 (depends on 21)

The process of claim 21, wherein the nucleophilic substitution is performed with an amine.

### Claim 24 (depends on 21)

The process of claim 21, wherein the reduced hydroxyphenone (R)-3-(Hydroxy-ethyl)phenol (compound VI) is converted to (S)-3-(1-Dimethylamino-ethyl)-phenol of structure (IX):

### Claim 25

A process for the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol of formula (IX) comprising:
(a) performing an asymmetric catalytic reduction using transfer hydrogenation on 1-(3-Hydroxy-phenyl)-ethanone (compound V) to form (R)-3-(1-Hydroxy-ethyl)-phenol (compound VI) as shown below:
(b) performing an activation step on the hydroxyl groups of the formed (R)-3-(1-Hydroxy-ethyl)-phenol to form activated hydroxy alcoholic groups and activated hydroxy phenolic groups on the (R)-3-(1-Hydroxy-ethyl)-phenol;
(c) performing a nucleophilic substitution on the activated hydroxy alcoholic groups; and
(d) cleaving the activated hydroxy phenolic groups;
wherein (S)-3-(1-Dimethylamino-ethyl)-phenol is formed.

### Claim 26

A process for the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol (compound IX), comprising:
(a) reducing 1-(3-hydroxy-phenyl)-ethanone of formula (V) to form (R)-3-(Hydroxy-ethyl)phenol of formula (VI);
(b) transforming (R)-3-(Hydroxy-ethyl)phenol (compound VI) to form (R)-methanesulfonic acid 3-(1-methanesulfonyloxy-ethyl)phenyl;
(c) performing a nucleophilic substitution on the activated hydroxy alcoholic groups utilizing dimethyl amine; and
(d) transforming (S)-methanesulfonic acid 3-(1-dimethylamino-ethyl)-phenyl ester to form the chiral (S)-3-(1-Dimethylamino-ethyl)-phenol.

### Claim 27 (depends on 24)

The process of claim 24, wherein the chiral (S)-3-(1-Dimethylamino-ethyl)-phenol (compound IX) obtained is further purified by a crystallization.

### Claim 28 (depends on 27)

The process of claim 27, wherein the crystallization is a kinetic crystallization.

### Claim 29 (depends on 21, 25, 26)

The process of claim 21, 25 or 26, wherein the reduced hydroxyphenone (R)-3-(Hydroxy-ethyl)phenol (compound VI) is converted to (S)-3-(1-Dimethylamino-ethyl)-phenol (compound IX) and wherein the enantiomeric ratio (S):(R) is 90:10 or higher.

### Claim 30 (depends on 1)

The process of claim 1, further comprising the step or steps to form rivastigimine in the form of a free base, a salt or a prodrug thereof.

### Claim 31 (depends on 25)

A process for the preparation of rivastigimine comprising:
(i) performing the process of claim 25
(ii) further acylating the (S)-3-(1-Dimethylamino-ethyl)-phenol (compound IX) to form rivastigimine,
wherein the phenolic hydroxy group of the resulting product is acylated with an acylating agent of the formula C2H5(CH3)NC(O)X, wherein X is OH or an activating group, e.g. halo to form [3-[(1S)-1-dimethylaminoethyl]phenyl]N-ethyl-N-methylcarbamate,
the process optionally further comprising resolving the end product of step (ii) to resolve [3-[(1S)-1-dimethylaminoethyl]phenyl]N-ethyl-N-methylcarbamate from its (1R)-isomer.

### Claim 32 (depends on 31)

The process of claim 31 further comprising:
(i) contacting the rivastigimine with a pharmaceutically acceptable acid to form an acid addition salt thereof; or
(ii) incorporating the rivastigimine into a drug delivery product; or
(iii) contacting the rivastigimine with a pharmaceutically acceptable acid to form an acid addition salt thereof and incorporating the rivastigimine into a drug delivery product.

### Claim at position 33

33-35. (canceled)

### Claim 36

A composition comprising (R)-methanesulfonic acid 3-(1-methanesulfonyloxy-ethyl)-phenyl ester or (S)-methanesulfonic acid 3-(1-methanesulfonyloxy-ethyl)-phenyl ester or a mixture thereof.

### Claim 37

A composition comprising (R)-methanesulfonic acid 3-(1-Dimethylamino-ethyl)-phenyl ester or (S)-methanesulfonic acid 3-(1-Dimethylamino-ethyl)-phenyl ester or a mixture thereof.

### Claim 38

A composition comprising (R)-3-(1-hydroxyethyl)-phenyl methanesulfonate or (S)-3-(1-hydroxyethyl)-phenyl methanesulfonate or a mixture thereof.

### Claim 39

A composition comprising (R)-1-(3-hydroxyphenyl)-ethyl methanesulfonate or (S)-1-(3-hydroxyphenyl)-ethyl methanesulfonate or a mixture thereof.
